Stockwinners Market Radar for May 22, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:13 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Chipmaker Broadcom (AVGO) is in talks to acquire cloud service provider VMware (VMW), Reuters' Greg Roumeliotis reported, citing people familiar with the matter. Negotiations between Broadcom and VMware are ongoing and a deal is not imminent, the sources said. Michael Dell is VMware's biggest investor with a 40% stake as a result of Dell Technologies (DELL)having spun out VMWare to its shareholders last year, according to Refinitiv data. 2. Amazon (AMZN), stuck with too much warehouse capacity now that the surge in pandemic-era shopping has faded, is looking to sublet at least 10 million square feet of space and could vacate even more by ending leases with landlords, Bloomberg's Spencer Soper reported, citing people familiar with the matter. The excess capacity includes warehouses in New York, New Jersey, Southern California and Atlanta, the people said. Amazon could try to negotiate lease terminations with existing landlords, including Prologis (PLD), an industrial real estate developer that counts the e-commerce giant as its biggest tenant, two of the people said. 3. After a bubbly year for initial public offerings, 2022 looks like a bust. Shares of many companies that came public last year are down 80% or more from their peaks, Andrew Bary wrote in this week's edition of Barron's. The wreckage has yielded some bargains, particularly in companies with good growth prospects and solid balance sheets. Some stocks to consider from the 2021 crop of IPOs, the author said, are Allbirds (BIRD), Poshmark (POSH), Robinhood (HOOD), and Warby Parker (WRBY). He also finds Rivian Automotive (RIVN) intriguing because its stock, which topped out at $179 after its IPO in November, got as low as $19 earlier in May. That valued the company at slightly more than the $15 billion of net cash on its balance sheet on March 31, the publication added. 4. Marvel Studios and Disney's (DIS) "Doctor Strange in the Multiverse of Madness" stayed atop the chart in its third outing with another $31.6M from 4,534 theaters for a domestic total of $342.1M and $803.2M globally. The movie starring Benedict Cumberbatch is now the number 2 film of the pandemic era behind "Spider-Man: No Way Home." 5. Genco Shipping & Trading (GNK) and Lindt & Spruengli (LDSVF) saw positive mentions in this week's edition of Barron's.

18:02 EDT Seres Therapeutics presents Phase 3 results of SER-109 for rCDI - Seres Therapeutics announced the presentation of data from its Phase 3 ECOSPOR III study that suggest investigational microbiome-based therapeutic SER-109 prevents recurrent C. difficile infections by rapidly establishing a long-lasting colony of beneficial gut microbes, which can produce fatty acids that disrupt the C. difficile lifecycle. These data were shared in oral and poster presentations at the 2022 Digestive Disease Week Annual Meeting. Seres expects to finalize a Biologics License Application submission for SER-109 with the U.S. Food and Drug Administration in mid-2022, positioning SER-109 up to potentially become the first ever FDA-approved microbiome-based therapeutic for treating recurrent C. difficile infections with a potential product launch in the first half of 2023. The ECOSPOR III Phase 3 study, a multicenter, randomized, placebo-controlled clinical trial that enrolled 182 adults with rCDI, previously demonstrated that SER-109 prevented rCDI in 88% of recipients at the eight-week primary endpoint, whereas only 60% in the placebo arm remained recurrence-free over the same time period. The safety profile was similar across both groups. A pre-planned exploratory analysis from the ECOSPOR III trial shows that approximately two-thirds of CDI recurrences occurred within the first two weeks following antibiotic treatment for CDI - the window of vulnerability - when the microbiome is further decimated and C. difficile spores, untouched by antibiotics, are free to germinate into toxin-producing vegetative bacteria. SER-109 introduces a diverse consortium of bacterial species into the gut in the form of spores, which rapidly germinate and incorporate themselves into the microbiome, showing up in the stool as vegetative bacteria. This process is called engraftment. Within a week of SER-109 treatment, the number of new bacterial species in stool increased and remained significantly higher than the placebo group for the entire 24-week study period. Bacterial diversity rebounded more slowly and to a lesser degree in the placebo group. The pattern of results was the same regardless of which antibiotic participants received, vancomycin or fidaxomicin. To better understand how SER-109 prevents rCDI on the molecular level in a post-hoc analysis, stool samples collected from ECOSPOR III participants were analyzed for changes in their microbial makeup and fatty acid concentrations across the eight weeks following SER-109 treatment. Fatty acids with long and medium carbon chain lengths, such as butyrate, valerate and hexanoate, have been shown to inhibit the growth of C. difficile. For participants who received SER-109, butyrate, valerate and hexanoate levels rapidly increased, starting within the two-week window of vulnerability, and remained significantly higher than the placebo group for the eight-week data analysis period. Among members of the placebo group who experienced a CDI recurrence, valerate levels tended to be lower compared to members of the placebo group who did not experience a recurrence, further suggesting that valerate plays a protective role against rCDI. These data and data published previously in the New England Journal of Medicine suggest that a two-pronged approach for the treatment of rCDI, with standard-of-care antibiotics to kill vegetative C. difficile bacteria followed by investigational agent SER-109 to repair the disrupted microbiome through engraftment of Firmicutes bacteria and the modulation of multiple metabolic pathways in the gut, may be effective.

16:03 EDT Regeneron announces results from Phase 3 trial evaluating Evkeeza in HoFH - Regeneron Pharmaceuticals announced results from a Phase 3 trial evaluating Evkeeza in children aged 5 to 11 with homozygous familial hypercholesterolemia. The trial met its primary endpoint, showing children who added investigational Evkeeza to other lipid-lowering therapies reduced their low-density lipoprotein-cholesterol by 48% at week 24 on average. Detailed results were presented at the 5th European Atherosclerosis Society Pediatric Familial Hypercholesterolemia symposium and will form the basis of a regulatory submission to the U.S. Food and Drug Administration later this year. Despite treatment with other lipid-lowering therapies, children entered the trial with an average LDL-C level of 264 mg/dL, more than twice the target for pediatric patients with HoFH. After 24 weeks of Evkeeza treatment, the Phase 3 trial met its primary endpoint with additional results showing that 79% of patients reduced their LDL-C by at least half; An absolute 132 mg/dL reduction in LDL-C from baseline, on average; Reductions in levels of all lipid endpoint parameters assessed, which were generally observed within the first 8 weeks of treatment. These lipid parameters were apolipoprotein B, non-high-density lipoprotein cholesterol, lipoprotein and total cholesterol. Evkeeza was generally well-tolerated with all patients completing the trial. The most common adverse events were throat pain as well as upper abdominal pain, diarrhea, headache and nasopharyngitis. There were 2 severe AEs, both of which were considered unrelated to treatment. The potential use of Evkeeza in HoFH patients aged 5 to 11 years is currently under clinical development, and its safety and efficacy have not been fully evaluated by any regulatory authority.

15:56 EDT Albertsons voluntarily recalls select ReadyMeals and deli-prepared items - Albertsons, in cooperation with its supplier Smithfield Packaged Meats, has voluntarily recalled seven ReadyMeals and deli-prepared products that contain a bacon topping due to possible contamination with metal pieces. The select ReadyMeals and deli-prepared items were available for purchase under the following store banners and locations: Albertsons, Safeway and Lucky located only in Colorado, Idaho, Montana, Nevada, North Dakota, Oregon, Utah, and Wyoming.